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INTRODUCTION
One of the major cardiovascular health problems is heart
failure, affecting around 26 million people worldwide, and
its prevalence is increasing (Savarese and Lund, 2017). In
the United States heart failure-related deaths was 89.5 per
100 000 population in 2009 and 96.9 in 2014 (Ni and Xu,
2015).
Conduction delays and dyssynchrony of regional contractil-
ity are associated with further deterioration of ventricular
function, and therefore cardiac resynchronisation therapy
(CRT) is used to restore myocardial contraction sequence.
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The cardiac resynchronisation therapy (CRT) survey II is a joint initiative between the European
Heart Rhythm Association and the Heart Failure Association. It compiles real world data about
cardiac resynchronisation therapy in European Society of Cardiology member states. 11 088 pa-
tients assigned to implantation of CRT with pacemaker function (CRT-P) or CRT with an incorpo-
rated defibrillator (CRT-D) were enrolled in the survey starting 1 October 2015 till 31 December
2016 and for each patient, an electronic case report form (eCRF) was completed. Each participat-
ing country had each eCRF data-point benchmarked against the total cohort. In total, 79 patients
were included from Latvia. The mean age of patients was 68.1, similar to the total cohort of other
ESC member states, and 21.8% of patients were female. Latvian patients compared to other
countries more often had permanent atrial fibrillation, NYHA class III and IV, ejection fraction
35 %. CRT-Ds and multipolar lead implantation rates were higher. Peri-procedural complication
rates were similarly low in both groups. At discharge, prescribed medication rates were similar but
more frequently MRAs, ivabradine and calcium channel blockers were prescribed and slightly less
frequently ACE inhibitors/ARBs were prescribed. The CRT survey II is a valuable resource that
describes ongoing practice of cardiac resynchronisation therapy around Europe and benchmark-
ing against the total cohort is nationally significant for each participating country.
Key words: demographic, medication therapy, heart failure.
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Along with optimal medical treatment for selected patients,
CRT is recommended with a high level of evidence
(Ponikowski et al., 2016).
CRT has shown improvement in symptoms, exercise toler-
ance, ventricular function and reduction of mortality
(Cazeau et al., 2001; Abraham et al., 2002; Cleland et al.,
2005; Moss et al., 2009). It has been suggested that ap-
proximately 10% of hospitalised heart failure patients
would meet criteria for CRT (Farwell et al., 2000). Mostly
evidence for recommendations of CRT comes from ran-
domised controlled trials (RCT) with selected patient
groups, while patient groups like elderly with more comor-
bidities are not widely represented (Dickstein et al., 2015).
The first European CRT survey was launched in 2008–2009
by the Heart Failure Association (HFA) and the European
Heart Rhythm Association (EHRA of the European Society
of Cardiology (ESC). It compiled real-life data of 13 ESC
countries and demonstrated that the patient population re-
ceiving CRT was broader than that recommended by guide-
lines and it showed that a significant fraction of patients of
those groups were not well represented in RCTs (Dickstein
et al., 2009).
On the basis of the CRT survey, HFA and EHRA initiated
the CRT survey II in 2015. It collected broader data com-
pared to the first survey, as well as represented trends of
changes in the CRT receiving population, since new guide-
lines were presented during the period between the two sur-
veys. All 47 ESC member states (ESCMS) were invited to
participate in the CRT survey and 42 of them agreed to par-
ticipate and actively included patients (Dickstein et al.,
2018).
The aim of this article is to compare CRT implantation data
in Pauls Stradiòð Clinical University Hospital with data
from other ESCMS.
MATERIALS AND METHODS
The survey was designed as a joint initiative between the
EHRA and HFA. The design and rationale were published
previously (Dickstein et al., 2015).
Of the 47 invited ESCMS, 42 participated in the CRT sur-
vey II and overall 288 centres actively included patients.
The study was designed to include all patients assigned to
de-novo implantation of CRT with pacemaker function
(CRT-P), CRT with an incorporated defibrillator (CRT-D),
an upgrade from a permanent pacemaker (PPM) or an im-
plantable cardioverter defibrillator (ICD). Initially, patient
inclusion period was planned nine months starting from 1
October 2015, but was extended by six months till 31 De-
cember 2016 to increase the sample size.
Each implanting centre completed a one-time site question-
naire that represented hospital infrastructure, population
served, and details of CRT device implantation routines.
For each consecutive patient survey, an investigator com-
pleted an electronic case report form (eCRF). ECRF
included information about patient demographics, past
medical history and major comorbidities, pre-implantation
clinical evaluation, implant procedure, complications and
adverse events during index hospitalisation.
No further follow-up data collection was planned, patient
anonymity was strictly provided and eCRT was reviewed
by ESC data protection consultants. Taking this into consid-
eration, the RSU Research Ethics Committee was informed
and no informed consents or approval from Ethics Commit-
tee were necessary.
The daily survey process was monitored by Tessa Baak at
Stavanger University Hospital, University of Bergen, Nor-
way. Data management and statistical analyses was con-
ducted by Institut für Herzinfarktforschung Ludwigshafen,
Germany. Each participating country had each eCRF data-
point benchmarked against the total cohort. Categorical
variables were displayed as absolute numbers and percent-
ages and continuous variables were displayed as means with
standard deviations or medians with interquartile range. To
detect statistical significance between groups, the Mann–
Whitney–Wilcoxon test was used for continuous variables
and Chi-squared test for categorical variables.
RESULTS
During the 15-month enrolling period (October 2015 to De-
cember 2016) there were 11 088 patients included in CRT
Survey II from 288 centres in 42 ESC countries. 79 patients
were enrolled in Pauls Stradiòð Clinical University Hospi-
tal.
Patient characteristics. The results of patient demographic
characteristics and data of past medical history are pre-
sented in Table 1. In Latvia, the mean age of patients was
68.1 years, which was similar to other countries. 21.8% of
CRT receivers were females compared to 24.3% in other
countries. Heart failure with ischaemic origin in both patient
groups was similar (42.3% vs 44.5%, OR 0.91, 95% CI
0.58–1.43). Thereby prior history of revascularisation and
myocardial infarction also were without major difference.
There were several differences in other major comorbidi-
ties. Latvian patients receiving cardiac resynchronisation
therapy more often had atrial fibrillation (55.1% vs 40.7%,
p = 0.01, OR 1.79, CI 95% 1.14–2.80) and 58.1% of them
had permanent form compared to 42.2% in patients of other
countries (OR 1.90, CI 95% 1.03–3.50). Furthermore, anae-
mia was more frequent in Latvian patients. On the other
hand, they suffered less from diabetes hypertension and ob-
structive lung disease.
Clinical evaluation. More patients assigned to cardiac re-
synchronisation therapy were in the New York Heart Asso-
ciation (NYHA) functional class III or IV in Latvia than in
other ESC countries (Table 2). While both groups had simi-
lar systolic blood pressure measurement, Latvian patients
had slightly higher diastolic blood pressure (76.2 ± 9.1 vs
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73.6 ± 11.5, p = 0.014). Several differences were observed
in pre-implantation ECG. Latvian patients displayed longer
PR interval (204 ± 51 vs 189 ± 50, p = 0.017) and QRS du-
ration (168 ± 31 vs 157 ± 27, p = 0.001). There was slightly
more left bundle brunch block (LBBB) and less right bun-
dle brunch block (RBBB) in Latvian patients, although not
reaching statistical significance. Latvian patients presented
with a better left ventricle (LV) ejection fraction (EF) than
other patients (31.6 ± 10.6 vs 28.4 ± 8.1, p = 0.022) and
consequently a higher percentage of patients had ejection
fraction > 35% (Table 3). However, end diastolic diameter
(EDD) was significantly wider in the Latvian population
(67.0 ± 8.4 vs 63.5 ± 9.1, p = 0.001) and 50% had at least
moderate mitral regurgitation.
CRT implantation procedure, complications. All CRT
implantation procedures during the inclusion period were
successful in Latvia (Table 4). Mean duration was signifi-
cantly longer than in other countries (131.8 ± 48.9 vs 99.6 ±
46.2, p < 0.0001) but there was no difference in fluoroscopy
time. In contrast to other countries, CRT-Ds were implanted
more than CRT-Ps in Latvia and a multipolar LV lead was
chosen more frequently. Complication rates were similar in
both groups — in total 5.1% Latvian patients and 5.6% pa-
tients of other ESC countries had peri-operative complica-
tions.
Discharge status. There were no deaths or major adverse
events (myocardial infarction, stroke, infection, worsening
heart failure, worsening renal function, arrhythmias) during
hospitalisation in the Latvian patient group. On the other
hand, these events occurred in 4.8% of patients in other
ESC member states (p = 0.046).
In post-implant ECG, mean QRS duration in the Latvian pa-
tient group was 155 ± 28 ms compared to 138 ± 24 ms in
the other patient group (p < 0.0001). The QRS width distri-
bution is presented in Figure 1.
The CRT survey II also compiled data on recommended
medications at discharge. There were several statistically
significant differences between Latvian patients and the to-
tal cohort (Table 5). Angiotensin converting enzyme inhibi-
tors (ACEi) or angiotensin receptor blockers (ARBs) were
prescribed in 78.2% of Latvian patients compared to 86.5%
of patients in other ESC countries (p = 0.034, OR 0.56, CI
95% 0.33–0.96); also beta-blockers were prescribed less of-
ten although without reaching statistical significance. Lat-
vian patients more often had mineralocorticoid receptor an-
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Table 1. Patient demographic characteristics and past history
Parameters Latvia, n = 77 All other countries, n = 10962 p-value OR (95%-CI)
Age, years 68.1 ± 9.3 68.5 ± 10.8 0.341
Median (1. quartile, 3. quartile) 68 (62, 75) 70 (62, 76)
5th and 95th percentile 53 , 83 (VIG) 49 , 84 (VIG)
Age < 65 33.8% (26/77) 31.5% (3452/10962) 1.11 (0.69–1.78)
65  Age < 75 40.3% (31/77) 36.4% (3994/10962) 1.18 (0.74–1.86)
Age  75 26.0% (20/77) 32.1% (3516/10962) 0.74 (0.45–1.24)
Gender 0.604
Male 78.2% (61/78) 75.7% (8305/10974) 1.15 (0.67–1.98)
Female 21.8% (17/78) 24.3% (2669/10974) 0.87 (0.51–1.49)
Elective admission 88.5% (69/78) 76.9% (8353/10868) 0.015 2.31 (1.15–4.63)
Referral from another centre 3.8% (3/78) 25.5% (2767/10860) 0 0.12 (0.04–0.37
Primary HF aetiology
Ischaemic 42.3% (33/78) 44.5% (4842/10875) 0.91 (0.58–1.43)
Non-ischaemic 44.9% (35/78) 49.8% (5418/10875) 0.82 (0.52–1.28)
Other 12.8% (10/78) 5.7% (615/10875) 2.45 (1.26–4.79)
Myocardial infarction 39.7% (31/78) 36.2% (3926/10848) 0.515 1.16 (0.74–1.83)
Prior revascularisation 41.0% (32/78) 38.8% (4213/10846) 0.694 1.10 (0.70–1.72)
Hypertension 39.7 % (31/78) 64.0% (6931/10822) 0 0.37 (0.23–0.58)
Atrial fibrillation 55.1% (43/78) 40.7% (4416/10842) 0.010 1.79 (1.14–2.80)
Paroxysmal 27.9% (12/43) 34.8% (1536/4416) 0.73 (0.37–1.42)
Persistent 11.6% (5/43) 22.4% (989/4416) 0.46 (0.18–1.16)
Permanent 58.1% (25/43) 42.2% (1864/4416) 1.90 (1.03–3.50)
Obstructive lung disease 6.4% (5/78) 12.1% (1310/10844) 0.125 0.50 (0.20–1.24)
Diabetes 17.9% (14/78) 31.5% (3414/10843) 0.010 0.48 (0.27–0.85)
Anaemia 23.1% (18/78) 15.0% (1622/10838) 0.046 1.70 (1.00–2.89)
Chronic kidney disease (GFR 60) 30.8% (24/78) 31.1% (3371/10829) 0.945 0.98 (0.61–1.59)
HF, heart failure; GFR, glomerular filtration rate, OR, odds ratio; p-value, statistical significance of difference between Latvian and other ESC mamber state
data, significant considered if < 0.05
tagonists and calcium channel blockers prescribed and
significantly greater percentage of ivabradine (25.6% vs
5.5%, p < 0.0001, OR 5.95, CI 95% 3.56–9.96).
DISCUSSION
The CRT survey II is a valuable resource describing the
“real world” CRT receiver population. Although the Lat-
vian sample size is not large, it clearly describes the
demographics of patients and post-implantation care after
receiving a CRT device. Moreover, it is an interesting tool
to compare data from a single implanting centre — Pauls
Stradiòð Clinical University Hospital — benchmarked
against a cohort of all other ESC member states.
Mean age of patients included in the survey was similar in
Latvia and other ESC countries. Usually, females in CRT
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Table 2. Clinical evaluation
Parameters Latvia All other countries p-value OR (95%-CI)
NYHA class < 0.0001
I 0% (0/78) 3.4% (370/10770)
II 19.2% (15/78) 37.8% (4068/10770) 0.39 (0.22–0.69)
III 73.1% (57/78) 54.3% (5852/10770) 2.28 (1.38–3.77)
IV 7.7% (6/78) 4.5% (480/10770) 1.79 (0.77–4.13)
BMI, kg/m² 29.9 ± 6.4, n = 13 27.9 ± 4.9, n = 10461 0.288
Diastolic blood pressure, mmHg 76.2 ± 9.1, n = 77 73.6 ± 11.5, n = 10625 0.014
Systolic blood pressure, mmHg 126.8 ± 15.3, n = 77 124.7 ± 18.9, n = 10628 0.127
Pre-implant ECG
Heart rate, bpm 70 ± 16, n = 77 72 ± 17, n = 10645 0.082
Atrial rhythm 0.094
Sinus 59.0% (46/78) 69.3% (7450/10758) 0.64 (0.41–1.00)
Atrial fibrillation 38.5% (30/78) 25.5% (2748/10758) 1.82 (1.15–2.88)
Atrial paced 2.6% (2/78) 2.8% (301/10758) 0.91 (0.22–3.74)
PR interval, ms 204 ± 51, n = 43 189 ± 50, n = 7231 0.017
AV block II/III 18.2% (14/77) 18.9% (2012/10623) 0.866 0.95 (0.53–1.70)
Intrinsic QRS duration, ms 168 ± 31, n = 78 157 ± 27, n = 9457 0.001
LBBB 80.8% (42/52) 75.2% (7796/10365) 0.355 1.38 (0.69–2.76)
RBBB 3.8% (2/52) 6.6% (686/10365) 0.422 0.56 (0.14–2.32)
Other 15.4% (8/52) 18.2% (1883/10365) 0.604 0.82 (0.38–1.74)
AV node ablation for pat with AF 23.3% (7/30) 30.4% (827/2720) 0.402 0.70 (0.30–1.63)
Performed 85.7% (6/7) 22.6% (187/827) 20.53 (2.46–171.64)
Planned 14.3% (1/7) 77.4% (640/827) 0.05 (0.01–0.41)
AF, atrial fibrillation; AV, atrioventricular; BMI, body mass index; NYHA, New York Heart Association; ECG, electrocardiogram; LBBB, left bundle
brunch block; RBBB, right bundle brunch block; p-value, statistical significance of difference between Latvian and other ESC mamber state data, significant
considered if < 0.05
Table 3. Echo data prior implantation
Echo parameters Latvia All other countries p-value OR (95%-CI)
LVEF, % 31.6 ± 10.6, n = 74 28.4 ± 8.1, n = 10731 0.022
LVEF, % < 25 21.6% (16/74) 27.6% (2963/10731) 0.72 (0.42–1.26)
25  LVEF, %  35 58.1% (43/74) 59.5% (6383/10731) 0.94 (0.59–1.50)
LVEF, % > 35 20.3% (15/74) 12.9% (1385/10731) 1.72 (0.97–3.03)
LVEDD by Echo, mm 67.0 ± 8.4, n = 68 63.5 ± 9.1, n = 8569 0.001
Mitral regurgitation 0.339
Mild 21.7% (13/60) 46.6% (4631/9940) 0.32 (0.17–0.59)
Moderate 43.3% (26/60) 26.4% (2620/9940) 2.14 (1.28–3.57)
Severe 6.7% (4/60) 6.9% (686/9940) 0.96 (0.35–2.67)
None 28.3% (17/60) 20.2% (2003/9940) 1.57 (0.89–2.75)
LVEDD, left ventricle end diastolic diameter; LVEF, left ventricle ejection fraction; p-value, statistical significance of difference between Latvian and other
ESC mamber state data, significant considered if < 0.05
trials form a significantly lower proportion of the study
population, which is true also in the CRT survey II, al-
though female gender is one of the factors predicting better
response to CRT. If we look at other major factors that are
associated with greater benefit from CRT (LBBB, wider
QRS than 150 ms, non-ischemic genesis of heart failure),
then also the CRT survey II showed that CRT receiving pa-
tients fulfil those criteria both in Latvia and other ESC
countries. However, there are patients who are not in the
zone that predicts greatest benefit of CRT (narrower QRS,
LVEF  35%, ischaemic HF genesis, non-LBBB). Latvian
patients more often had LVEF 35%, although mean EF
was not much different to other countries. Reduced LVEF,
being one of the main criteria for CRT device implantation,
is also a slightly dynamic parameter affected by patient clin-
ical status at the time of examination, action of heart failure
compensatory mechanisms, and also inter-observer variabil-
ity for LVEF measured by two dimensional echocardio-
graphy is quite significant. CRT in patients with LVEF >
35% is still an important question for discussion, which is
too complicated to be proved through large randomised tri-
als. (Linde et al., 2016). However, it has been shown that
patients with NYHA class III–IV status, and QRS > 130 ms
appear to derive clinical and structural benefit from CRT
(Chung et al., 2010). Moreover, in the presence of EF
36%–50%, left bundle brunch block is related to worse clin-
362 Proc. Latvian Acad. Sci., Section B, Vol. 74 (2020), No. 6.
Table 4. Procedure related parameters and complications
Parameters Latvia All other countries p-value OR (95%-CI)
Admission to implantation, day 2.4 ± 2.4, n = 80 3.9 ± 9.4, n = 10907 0.533
Type of device 0.010
CRT-P 16.9% (13/77) 30.3% (3243/10692) 0.47 (0.26–0.85)
CRT-D 83.1% (64/77) 69.7% (7449/10692) 2.14 (1.18–3.90)
Duration, min 131.8 ± 48.9, n = 80 99.6 ± 46.2, n = 10347 0
Fluoroscopy time, min 17.5 ± 16.7, n = 71 17.8 ± 17.1, n = 10271 0.324
LV lead placement successful 98.2% (54/55) 99.4% (10479/10539) 0.222 0.31 (0.04–2.27)
Lead placement epicardially 7.4% (4/54) 9.2% (963/10479) 0.79 (0.28–2.19)
LV lead type 0.024
Unipolar 0% (0/62) 0.7% (77/10539)
Bipolar 29.0% (18/62) 42.3% (4460/10539)
Multipolar 71.0% (44/62) 57.0% (6002/10539)
Complication 5.1% (4/79) 5.6% (620/11009) 0.827 0.89 (0.33–2.45)
Death 0% (0/79) 0.1% (8/11009) 0.811
Bleeding 1.3% (1/79) 1.0% (107/11009) 0.791 1.31 (0.18–9.48)
Requiring intervention 0% (0/79) 0.3% (35/11009) 0.616
Pocket haematoma 1.3% (1/79) 0.8% (84/11009) 0.610 1.67 (0.23–12.13)
Pneumothorax 1.3% (1/79) 1.0% (111/11009) 0.820 1.26 (0.17–9.13)
Haemothorax 0% (0/79) 0.1% (9/11009) 0.799
Coronary sinus dissection 0% (0/79) 1.9% (214/11009) 0.211
Pericardial tamponade 0% (0/79) 0.3% (28/11009) 0.654
Other 2.5% (2/79) 1.5% (170/11009) 0.479 1.66 (0.40–6.80)
CRT-D, cardiac resyhchronization therapy with incooperaed defibrilaor, CRT-P, cardiac resynchronization therapy with pacemaker function; LV, left ventri-
cle
Fig. 1. Post – implant QRS
ical outcomes than for no conduction abnormality (Witt et
al., 2016). Considering that more Latvian patients had
NYHA class III-IV and LBBB, it seems that patient clinical
status and possibility of LVEF dynamic worsening in near
future play important roles in decisions for CRT implanta-
tion. This may reflect that CRT implanters mostly adhere to
guidelines, and their implanting centre experience may also
play an important role in deciding if patients need cardiac
resynchronisation therapy.
Significantly more patients in Latvia had atrial fibrillation,
with almost 70% having either the persistent or permanent
form. Since 2013, CRT is a IIa recommendation in patients
with atrial fibrillation if strict rate control can be provided
(Bringole et al., 2013). High atrial rates is one of the main
reasons for loss of biventricular pacing and significant re-
duction in mortality has been observed when biventricular
pacing is more than 98% (Hayes et al., 2011). In 23.3% of
LV patients with permanent atrial fibrillation AV nodal ab-
lation was done or planned without statistically significant
differences from other ESCMS. The results of cardiac re-
synchronisation in patients with atrial fibrillation could be
an important question to study further, also locally.
Differences were observed also in the rates of other comor-
bidities. Latvian patients presented with less diabetes, hy-
pertension and obstructive lung disease, while another study
describing the Latvian CRT receiver population showed that
more than 70% of them had a previous history of smoking.
This also could show gaps in chronic disease diagnostics at
the primary care setting. More notably, more comorbidities
have not been shown to reduce the response to CRT (Zeitler
et al., 2017; Barra et al., 2017).
Regarding the devices used in cardiac resynchronisation
therapy, a CRT-D ratio to CRT-P was higher in Latvia than
in other ESCMS. This ratio may reflect good guideline ad-
herence as patients with an EF  35% have a guideline indi-
cation for a device with defibrillator function (Ponikowski
et al., 2016). Furthermore, multipolar left ventricular leads
were more often used in the Latvian population. Multipolar
LV leads compared to bipolar LV leads allow lower LV
pacing threshold and decrease the possibility of phrenic
nerve stimulation (Gurevitz et al., 2005).
Furthermore, together with the indications for CRT of EF <
35% and wide QRS, patients also should be symptomatic
despite optimal medical treatment. Although the CRT sur-
vey II did not include questions about medical treatment
prior to the implantation, data about drug therapy at dis-
charge were compiled. There were some statistically signifi-
cant differences observed. An important finding was
slightly lower ACI/ARB prescription rates in the LV popu-
lation. 78.2% of Latvian patients received ACI/ARBs com-
pared to 86.5% in other countries (p = 0.034). Furthermore,
the percentage of ACI/ARBs receivers with reduced ejec-
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Table 5. Drug therapy at discharge
Drugs Latvia All other countires p-value OR (95%-CI)
Loop diuretic 79.5% (62/78) 81.1% (8559/10557) 0.722 0.90 (0.52–1.57)
ACE inhibitor/ARB 78.2% (61/78) 86.5% (9102/10525) 0.034 0.56 (0.33–0.96)
MRA (aldosterone antagonist) 76.6% (59/77) 63.1% (6623/10496) 0.014 1.92 (1.13–3.25)
Betablocker 83.3% (65/78) 89.0% (9407/10570) 0.112 0.62 (0.34–1.12)
Ivabradine 25.6% (20/78) 5.5% (573/10465) 0 5.95 (3.56–9.96)
Digoxin 9.0% (7/78) 10.4% (1093/10466) 0.672 0.85 (0.39–1.84)
Calcium channel blocker 15.4% (12/78) 8.9% (934/10453) 0.047 1.85 (1.00–3.44)
Amiodarone 12.8% (10/78) 17.3% (1815/10469) 0.293 0.70 (0.36–1.36)
Other anti-arrhythmic agent 5.1% (4/78) 1.7% (177/10453) 3.14 (1.13–8.68)
Oral anticoagulant 50.0% (39/78) 46.6% (4889/10499) 0.545 1.15 (0.73–1.79)
Warfarin (Coumadin) 79.5% (31/39) 70.2% (3432/4889) 0.206 1.65 (0.75–3.59)
Dabigatran 10.3% (4/39) 6.6% (323/4889) 0.362 1.62 (0.57–4.57)
Rivaroxaban 10.3% (4/39) 12.4% (607/4889) 0.684 0.81 (0.29–2.28)
Apixaban 0% (0/39) 10.4% (509/4889) 0.033
Edoxaban 0% (0/39) 0.4% (18/4889) 0.704
No oral anticoagulant 50.0% (39/78) 53.4% (5610/10499) 0.545 0.87 (0.56–1.36)
Anti-platelet agent 39.2% (31/79) 43.7% (4815/11009) 0.422 0.83 (0.53–1.31)
Aspirin 33.3% (26/78) 41.4% (4331/10469) 0.151 0.71 (0.44–1.14)
Clopidogrel 9.0% (7/78) 12.4% (1297/10469) 0.361 0.70 (0.32–1.52)
Ticagrelor 1.3% (1/78) 1.3% (135/10469) 0.995 0.99 (0.14–7.20)
Prasugrel 0% (0/78) 0.3% (31/10469) 0.630
Dual anti-platlet therapy 3.8% (3/78) 9.3% (978/10469) 0.096 0.39 (0.12–1.23)
Oral anticoagulation and P2Y12 Inhibitor 5.1% (4/78) 4.1% (436/10542) 0.661 1.25 (0.46–3.44)
Triple Therapy 1.3% (1/78) 2.1% (217/10543) 0.630 0.62 (0.09–4.46)
ACE, angiotensin converting enzyme; ARB angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist
tion fraction in the ESC-HF Long-Term Registry was
92.2% (Maggioni et al., 2013). This could be another im-
portant question for further investigation, because the indi-
cation for angiotensin receptor neprilysin inhibitor was in-
cluded in the HF guidelines during the patient inclusion
period in the CRT survey II. In contrast, MRAs was pre-
scribed significantly more often in Latvian population.
An interesting finding was that ivabradine was prescribed
almost five times more in Latvian patients. Regarding the
prescription rate of beta-blockers, there was a statistically
non-significant lower prescription rate in the Latvian pa-
tients. Although the CRT survey II did not collect data
about medication dosage, we might speculate that probably
we do not reach target doses of beta blockers in Latvia
andthat this led to more frequent prescription of ivabradine.
Although the main beta-blocker trials are designed to reach
target doses of beta-blockers, it has been shown that
beta-blocker usage at any dose and reaching the target heart
rate might be more important than a maximal beta-blocker
dose (Cullington et al., 2012; Swedberg et al., 2012). In
ESC Heart failure guidelines, 2016 ivabradine is recom-
mended if a patient with HFrEF and sinus rhythm is still
symptomatic after using ACIs, MRAs, Betablockers in
maximal tolerated doses and heart rate  70 x/min. In the
SHIFT study, where ivabradine was compared to a placebo
for patients with HFrEF, the ivabradine group had reduced
rates of morbidity and mortality due to heart failure
(Swedberg et al., 2010).
Thus, CRT II shows not only the particulars of patient se-
lection for CRT and with implantation procedure related
data but also insights into overall heart failure medication
therapy in Latvia and in other ESC member states.
CONCLUSION
The CRT survey II enrolled 11 088 patients that received
cardiac resynchronisation therapy in ESC member states
and there were 79 patients included in the Pauls Stradiòð
Clinical University Hospital. Compared to other countries,
Latvian patients more often had atrial fibrillation and espe-
cially a permanent form, more were in NYHA classes III
and IV. Similarly, the majority of patients had complete
LBBB, but Latvian patients more often had EF > 35%, al-
though EDD was wider in the Latvian population. Latvian
patients more frequently received CRT-Ds and quadripolar
leads, peri-procedural complication rates were similarly low
and post-implantation QRS was wider in LV patients. The
CRT survey II also demonstrated differences in heart failure
drug therapy between both patient groups. For example,
Latvian patients received more MRAs, ivabradine and CCB
and less ACE inhibitors. In summary, the majority of pa-
tients fulfil the recommendations of guidelines, but a signif-
icant number of patients who receive a CRT device receive
it, without strong background of evidence from randomised
controlled trials, and the CRT survey II is a valuable source
for further research in those groups.
REFERENCES
Abraham, W. T., Fisher, W. G., Smith, A. L., Delurgio, D. B., Leon, A. R.,
Loh, E., Kocovic, D. Z., Packer, M., Clavell, A. L., Hayes, D. L et al.
(2002). Cardiac resynchronization in chronic heart failure. New Engl. J.
Med., 346 (24), 1845–1853.
Barra, S., Providência, R., Agarwal, S., Marijon, E., Boveda, S. (2017). The
benefit of cardiac resynchronization therapy is not hindered by the number
of comorbidities. J. Amer. Coll. Cardiol., 70 (16), 2096–2097.
Brignole, M., Auricchio, A., Baron-Esquivias, G., Bordachar, P., Boriani, G,
Breithardt, O. A., Cleland, J., Deharo, J. C, Delgado, V., Elliott, P. M. et al.
(2013). 2013 ESC Guidelines on cardiac pacing and cardiacre-
synchronization therapy. Eur. Heart J., 34, 2281–2329.
Cazeau, S., Leclercq, C., Lavergne, T., Walker, S., Varma, C., Linde, C.,
Garrigue, S., Kappenberger, L., Haywood, G. A., Santini, M., Bailleul, C.,
Daubert, J. C., Multisite Stimulation in Cardiomyopathies (MUSTIC)
Study Investigators (2001). Effects of multisite biventricular pacing in pa-
tients with heart failure and intraventricular conduction delay. New Engl. J.
Med., 344 (12), 873–880.
Chung, E. S., Katra, R. P., Ghio, S., Bax, J., Gerritse, B., Hilpisch, K., Peter-
son, B. J., Feldman, D. S., Abraham, W. T. (2010). Cardiac resynchroni-
zation therapy may benefit patients with left ventricular ejection fraction
35%: a PROSPECT trial substudy. Eur. J. Heart Failure, 12 (6), 581–587.
Cleland, J. G. F., Daubert, J.-C., Erdmann, E., Freemantle, N., Gras, D.,
Kappenberger, L., Tavazzi, L. (2005). The effect of cardiac resynchroni-
zation on morbidity and mortality in heart failure. New Engl. J. Med., 352,
1539–1549.
Cullington, D., Goode, K. M., Clark, A. L., Cleland, J. G. (2012), Heart rate
achieved or beta-blocker dose in patients with chronic heart failure: Which
is the better target? Eur. J. Heart Failure, 14, 737–747.
Dickstein, K., Bogale, N., Priori, S., Auricchio, A., Cleland, J. G., Gitt, A.,
Limbourg, T., Linde, C., van Veldhuisen, D. J., Brugada, J., Scientific
Committee, National Coordinators (2009). The European cardiac
resynchronization therapy survey. Eur. Heart J., 30 (20), 2450–2460.
Dickstein, K., Normand, C., Anker, S. D., Auricchio, A., Blomström-
Lundqvist, C., Bogale, N., Cleland, J., Filippatos, G., Gasparini, M., Gitt,
A., Hindricks, G., Kuck, K.H., Ponikowski, P., Stellbrink, C., Ruschitzka,
F., Linde, C. (2015). European Cardiac Resynchronization Therapy Survey
II: rationale and design. EP Europace, 17 (1), 137–141.
Dickstein, K., Normand, C., Auricchio, A., Bogale, N., Cleland, J. G., Gitt,
A. K., Stellbrink, C., Anker, S. D., Filippatos, G., Gasparini, M. et al.
(2018). CRT Survey II: a European Society of Cardiology survey of car-
diac resynchronisation therapy in 11 088 patients — who is doing what to
whom and how? Eur. J. Heart Failure, 20, 1039–1051.
Farwell, D., Patel, N. R., Hall, A., Ralph, S., Sulke, A. N. (2000). How many
people with heart failure are appropriate for biventricular resynchro-
nization? Eur. Heart J., 21 (15), 1246–1250.
Gurevitz, O., Nof, E., Carasso, S., Luria, D., Bar-Lev, D., Tanami, N., Eldar,
M., Glikson, M. (2005). Programmable multiple pacing configurations
help to overcome high left ventricular pacing thresholds and avoid phrenic
nerve stimulation. Pacing Clin. Electrophysiol., PACE, 28 (12),
1255–1259.
Hayes, D. L., Boehmer, J. P., Day, J. D., Gilliam, F. R., 3rd, Heidenreich, P.
A., Seth, M., Jones, P. W., Saxon, L. A. (2011). Cardiac resynchronization
therapy and the relationship of percent biventricular pacing to symptoms
and survival. Heart Rhythm, 8 (9), 1469–1475.
Linde, C., Curtis, A. B., Fonarow, G. C., Lee, K., Little, W., Tang, A., Levya,
F., Momomura, S., Manrodt, C., Bergemann, T., Cowie, M. R. (2016). Car-
diac resynchronization therapy in chronic heart failure with moderately re-
duced left ventricular ejection fraction: Lessons from the Multicenter
InSync Randomized Clinical Evaluation MIRACLE EF study. Int. J.
Cardiol., 202, 349–355.
Maggioni, A.P., Anker, S.D., Dahlström, U., Filippatos, G., Ponikowski, P.,
Zannad, F., Amir, O., Chioncel, O., Leiro, M.C., Drozdz, J., Erglis, A. et al.
(2013). Are hospitalized or ambulatory patients with heart failure treated in
364 Proc. Latvian Acad. Sci., Section B, Vol. 74 (2020), No. 6.
accordance with European Society of Cardiology guidelines? Evidence
from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur. J.
Heart Failure, 15, 1173–1184.
Moss, A. J., Hall, W. J., Cannom, D. S., Klein, H., Brown, M. W., Daubert, J.
P., Estes, N. A. 3rd, Foster, E., Greenberg, H., Higgins, S. L., Pfeffer, M.
A., Solomon, S. D., Wilber, D., Zareba, W. (2009). Cardiac-resynchro-
nization therapy for the prevention of heart-failure events. New Engl. J.
Med., 361, 1329–1338.
Ni, H., Xu, J. (2015). Recent trends in heart failure-related mortality: United
States, 2000–2014. NCHS data brief, (231), 1–8.
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. H.,
Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V. P.,
Jankowska, E. A. et al. (2016). 2016 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure. Eur. J. Heart Failure, 18 (8),
891–975.
Savarese, G., Lund, L. H. (2017). Global public health burden of heart fail-
ure. Cardiac Failure Rev., 3 (1), 7–11.
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama,
A., Lerebours, G., Tavazzi, L., SHIFT Investigators (2010). Ivabradine and
outcomes in chronic heart failure (SHIFT): A randomised placebo-con-
trolled study. Lancet, 376 (9744), 875–885.
Swedberg, K., Komajda, M., Böhm, M., Borer, J., Robertson, M., Tavazzi,
L., Ford, I., SHIFT Investigators (2012). Effects on outcomes of heart rate
reduction by ivabradine in patients with congestive heart failure: Is there an
influence of beta-blocker dose? J. Amer. Coll. Cardiol., 59 (22),
1938–1945.
Witt, C. M., Wu, G., Yang, D., Hodge, D. O., Roger, V. L., Cha, Y. M.
(2016). Outcomes with left bundle branch block and mildly to moderately
reduced left ventricular function. JACC. Heart Failure, 4 (11), 897–903.
Zeitler, E. P., Friedman, D. J., Daubert, J. P., Al-Khatib, S. M., Solomon, S.
D., Biton, Y., McNitt, S., Zareba, W., Moss, A. J., Kutyifa, V. (2017). Mul-
tiple comorbidities and response to cardiac resynchronization therapy:
MADIT-CRT long-term follow-up. J. Amer. Coll.Cardiol., 69 (19),
2369–2379.
365Proc. Latvian Acad. Sci., Section B, Vol. 74 (2020), No. 6.
OTRÂ EIROPAS SIRDS RESINHONIZÂCIJAS TERAPIJAS APTAUJA (CRT SURVEY II): LATVIJAS UN EIROPAS DATU
SALÎDZINÂJUMS
CRT survey II ir Eiropas Sirds ritma asociâcijas (Europian Heart Rhythm Association (EHRA) un Sirds Mazspçjas asociâcijas (Heart Fail-
ure Association (HFA)) kopîga iniciatîva. Ðî aptauja apkopo “reâlâs dzîves” datus par sirds resinhronizâcijas terapiju Eiropas Kardiologu
biedrîbas dalîbvalstîs. Laika posmâ no 2015. gada 1. oktobra lîdz 2016. gada 31. decembrim tika iekïauti 11 088 pacienti, kuriem tika
implantçta sirds resinhronizâcijas ierîce ar stimulatora funkciju (CRT-P) vai sirds resinhronizâcijas ierîce ar defibrilatora funkciju (CRT-D),
un par katru pacientu tika aizpildîta elektroniska klîniskâ gadîjuma forma. Visas dalîbvalstis saòçma analîzi par katru elektroniskâs formas
parametru, kas tika salîdzinâts ar kopçjo kohortu. Lîdzîgi citu valstu datiem vidçjais Latvijas pacientu vecums bija 68,1 gads, un 21,8% bija
sievietes. Latvijas pacientiem salîdzinoði bieþâk bija diagnosticçta âtriju fibrilâcija, viòiem bija sirds mazspçjas III un IV NYHA
funkcionâlâ klase un izsviedes frakcija 35%. Bieþâk tika implantçti CRT-D un lietoti multipolâri elektrodi. Lîdzîgi kâ kopçjâ Eiropas valstu
kohortâ, periprocedurâlas komplikâcijas bija sastopamas reti. Lîdzîgi râdîtâji bija arî izrakstîtajiem medikamentiem, izrakstoties no
stacionâra, bet bieþâk latvieðu pacienti saòçma minerâlkortikoîdu receptoru antagonistus, ivabradînu un kalcija kanâlu blokatorus, savukârt
nedaudz retâk tika izrakstîti angiotensîna konvertçjoðâ enzîma inhibitori vai angiotensîna receptoru blokatori. CRT survey II ir vçrtîgs
apkopojums par paðreizçjo praksi Eiropâ sirds resinhronizâcijas terapijas pielietoðanâ, kâ arî lokâli nozîmîga katrai valstij bija tâs datu
salîzinâðana ar kopçjo Eiropas kohortu.
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